Company Overview
Immuron Limited functions as a biopharmaceutical entity dedicated to the research, development, and commercialization of polyclonal antibodies across the markets of Australia, the United States, and Canada. The company operates within the healthcare sector, specifically under the biotechnology industry, a classification that denotes its focus on innovative medical solutions derived from biological processes. As of the latest reporting period, the company maintains a market capitalization of $8.22M and reports an annual revenue of $7.48M. With an employee count of 7, the organization operates with a very small workforce relative to its reported revenue figures. This combination of a $8.22M market cap and $7.48M in revenue indicates that Immuron is a micro-cap entity operating at a scale typical for early-stage biotechnology firms where significant value is often tied to pipeline potential rather than current earnings power. The minimal staff size of 7 employees suggests a lean operational structure, which is common in research-focused biotechnology companies but requires careful management of resources to sustain development activities.
Financial Health
The company reported a revenue of $7.48M over the trailing twelve months, yet this revenue generated a net income of $-4,646,242, revealing a substantial gap between top-line generation and bottom-line profitability. This disparity indicates a cost structure heavily weighted toward research, development, and operational expenses that exceed the gross profit generated from sales. The company's EBITDA stands at $-4,739,534, further highlighting that operating cash generation is currently insufficient to cover the costs of doing business without external capital injection. Free cash flow for the period was $-3,420,940, which signifies that the company is burning cash and lacks the internal financial flexibility to fund operations or growth without raising additional equity or debt. Analyzing the margins reveals a gross margin of 63.7%, suggesting favorable pricing or low cost of goods sold relative to revenue, but this is offset by an operating margin of -47.2% and a profit margin of -62.1%. These negative operating and profit margins indicate that while the product cost structure is efficient, the broader operational overhead and R&D expenditures are consuming the majority of the gross profit. The balance sheet shows a cash position of $10.00M against a debt level of $203,914, creating a scenario where liquidity assets significantly outweigh liabilities. The debt-to-equity ratio is 1.56, a figure that typically suggests leverage, yet in the context of a negative equity environment common in biotech, this metric requires careful interpretation regarding the company's capital structure. The current ratio is 8.04, which indicates a robust short-term liquidity position where current assets are eight times greater than current liabilities. Return on Equity is -39.7% and Return on Assets is -21.9%, metrics that reveal that management is currently unable to generate positive returns on the capital invested or the assets employed due to ongoing losses.
Valuation Assessment
The trailing twelve-month P/E ratio is listed as N/A due to the absence of net income, while the forward P/E is -80.49. The difference between a non-existent trailing P/E and a negative forward P/E implies that the market is pricing in a long period of negative earnings before the company can become profitable. The price-to-book ratio stands at 29.22, which indicates a significant market premium over the company's book value, a common valuation characteristic for speculative biotechnology stocks where the market values future intellectual property potential over current asset values. Alternative valuation metrics include a price-to-sales ratio of 1.10 and an EV/EBITDA of -53.41. These alternative metrics suggest that the company is being valued based on its sales generation capabilities rather than earnings, as traditional earnings-based multiples are not applicable to a loss-making entity. The stock traded with a 52-week high of $2.39 and a 52-week low of $0.68. Without a specific current price provided in the facts to calculate the exact percentage, the trading range demonstrates high volatility within a $1.71 spread between the high and low. The beta is 0.43, which means the stock price exhibits significantly lower volatility relative to the broader market, moving less than half as much as the market index on average.
Growth & Income
The revenue growth year-over-year is 4.8%, while earnings growth is listed as N/A due to the company's lack of profitability. Since earnings growth cannot be calculated when net income is negative, the comparison implies that the company is currently in an investment phase where revenue expansion is the primary metric of success rather than earnings acceleration. The company does not pay dividends, as indicated by a dividend yield of N/A and a payout ratio of 0.0%. This lack of dividend distribution means the company reinvests all available cash flow, however negative it may be, back into research and development to pursue growth objectives rather than returning capital to shareholders. The overall growth and income profile is characterized by modest top-line expansion coupled with significant cash burn and no current income distribution.